# US 2015/0105436 A1 · Methods and Assays for Detecting and Treating Hypoglycemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105436 A1
- Document ID: US20150105436A1
- Status: Published application
- Kind: A1
- Application number: 14/513,950
- Filed: 2014-10-14
- Published: 2015-04-16
- Earliest claimed: 2008-03-12
- Assignees: BioCrine AB
- Applicants: Biocrine AB
- Inventors: Per-Olof Berggren; Alejandro Caicedo; Over Cabrera
- Web page: https://patentgrep.com/patent/US20150105436A1

## CPC

- A61K 31/42: Oxazoles
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/502: {for testing non-proliferative effects}
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for heating hypoglycemia. The methods are useful for treating diabetes melititus and screening drug candidates for potential efficacy.

## Claims

### Claim 1

A method of treating hypoglycemia comprising administering an effective amount of a compound that activates an ionotropic glutamate receptor to stimulate glucagon release.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound activates the glutamate receptor subunit GluR6.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ionotropic glutamate receptor is a AMPA/kainate type receptor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of kainate, AMPA, and (2S,4R)-4-Methylglutamic acid, (RS)-2-Amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid, 4,6-Bis(benzoylamino)-1,3-benzenedicarboxylic acid, (±)-4-(4-Aminophenyl)-1,2-dihydro-1-methyl-2-propylcarbamoyl-6,7-methylenedioxyphthalazine, 1-(4′-Aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin-4-one, 1,4-Dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione hydrochloride, GABA, and Bicuculline.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is a glutamate analog.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound is administered at a dose of about 5 mg/kg/day to about 200 mg/kg/day.

### Claim 7 (depends on 1)

The method of claim 1, wherein the hypoglycemia is associated with diabetes mellitus.

### Claim 8

(canceled)

### Claim 9

A method of stimulating glucagon release comprising administering a compound that activates glutamate receptor subunit GluR6 of an ionotropic glutamate receptor to stimulate glucagon release.

### Claim 10 (depends on 9)

The method of claim 9, wherein the ionotropic glutamate receptor is a AMPA/kainate type receptor.

### Claim 11 (depends on 9)

The method of claim 9, wherein the compound is selected from the group consisting of kainate, AMPA, and GABA.

### Claim 12 (depends on 9)

The method of claim 9, wherein the compound is a glutamate analog.

### Claim 13 (depends on 9)

The method of claim 9, wherein the compound is administered at a dose of about 5 mg/kg/day to about 200 mg/kg/day.

### Claim 14

An assay for in vitro screening for modulators useful in treating diabetes comprising: providing islet cells in two groups, wherein the first group is a control and the second group is administered a dose of streptozotocin sufficient to destroy the .beta, cells present; administering a test compound to both the first and second group; and measuring the potentiation of glucagon release in the first and second groups to determine the effect of the test compound, wherein a decreased in cytoplasmic calcium mobilization and/or glucagon release is indicative of a compound that is useful as a modulator.
